ERNA Eterna Therapeutics, Inc.: Multiplikator forward rega marang pendapatan

Eterna Therapeutics (ERNA) minimizes scientific risks by allocating resources across various cell engineering programs. A safe method for the temporary modification of genetic code creates a unique advantage in blood therapy. However, the lack of current commercial revenue and the preclinical testing stage are weighing on the share price. The forward P/S valuation metric reflects the relationship between value and projected sales, where the value 26.40 expresses the level of this metric.

Eterna Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ERNA (periode 15.11.2023 - 09.11.2025)

Eterna Therapeutics Inc. - rincian analitis lan metrik utama (ERNA)

- rega saiki lan proyeksi nilai saham:

Rega saham Eterna Therapeutics Inc.|ERNA - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Biji pasar Eterna Therapeutics|ERNA - Total Nilai Bisnis

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Eterna Therapeutics|ERNA - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku eternatx.com|ERNA - Nilai Agregat Aset

- statistik kawajiban utang lan likuiditas:

Utang marang Ekuitas Eterna Therapeutics|ERNA - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Eterna Therapeutics, Inc.|ERNA - Gunggung utang perusahaan|Utang marang nilai buku Eterna Therapeutics, Inc.|ERNA - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Eterna Therapeutics|Rasio cepet eternatx.com

- rincian asil keuangan lan kelipatan valuasi:

ERNA - Bathi pungkasan|Proyeksi bathi mangsa ngarep Eterna Therapeutics|ERNA - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Eterna Therapeutics|ERNA - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Eterna Therapeutics|ERNA - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Eterna Therapeutics|ERNA - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan eternatx.com|ERNA - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Eterna Therapeutics

- rincian pendapatan lan dodolan:

ERNA - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan Eterna Therapeutics Inc.|ERNA - Kapitalisasi marang volume dodolan|Multiplikator Forward P/S Eterna Therapeutics Inc

Analisis fundamental perusahaan:Eterna Therapeutics Inc. (ERNA)

Forward P/S measures the market value of a business relative to projected revenue, allowing investors to assess the extent of sales growth expectations priced in. Analyzing the P/S expectations for Eterna Therapeutics (ERNA) reveals how production outsourcing via CMO platforms reduces capital expenditures, making the asset's current valuation more resilient to operational risks.

Pesaing wigati

TG Therapeutics - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Arcellx Therapeutics ACLX|discmedicine.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep syndax.com|Kura Oncology (KURA) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan ADC Therapeutics Corp|FHTX (foghorntx.com) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan VOR|Multiplikator forward rega marang pendapatan NKTX (Nkarta, Inc.)|Rasio rega marang pendapatan sing dikarepake COEP|Multiplikator Forward P/S ATNM (Actinium Pharma)|Estrella Immunopharma Inc - Rasio rega marang prakiraan pendapatan|CASI Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rega forward marang dodolan MRKR (Marker Therapeutics Inc)|IN8bio, Inc. - Rasio kapitalisasi marang dodolan sing dikarepake|GT Biopharma, Inc. - Rega forward marang dodolan|APTO (Aptose Biosciences) - Multiplikator Forward P/S|BPTH: Rega forward marang dodolan|Multiplikator Forward P/S MEIP|VINC (Vincerx Pharma) - Rega forward marang dodolan